Close Menu

NEW YORK – The US Food and Drug Administration has approved GlaxoSmithKline's PARP inhibitor niraparib (Zejula) as a first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of their biomarker status.

Less than 50 percent of women with advanced ovarian cancer live for five years. "This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend the time it takes for their cancer to progress," GSK CSO Hal Barron said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.

Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.

The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.